Phase 4 N=350 Safety and Efficacy of Intravenous Hydromorphone in Elderly Emergency Department Patients With Acute Severe Pain
Pain
Primary: Number of Patients With Successful Treatment — 127; 137; 26; 29 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=80 Intrathecal Hydromorphone for Pain Control After Cesarean Section
Pain · Cesarean Section
Primary: Post Operative Fentanyl PCA Consumption — 300; 446 µg
Phase 4 N=215 Titration of Intravenous Hydromorphone
Acute Severe Pain
Primary: Number of Participants Requesting Pain Medication in Different Patterns Over Time — 94; 20; 22; 19 Participants
Phase 4 N=50 Comparison of Side Effects of Morphine and Hydromorphone Patient-Controlled Analgesia (PCA)
Post Operative Pain
Primary: Nausea Assessment by Patient — 4.6; 3.0 Units on a scale
Phase 3 N=504 A Study of the Effectiveness and Safety of Sustained-release Hydromorphone (a Strong Opioid) in Patients With Chronic Noncancer Pain.
Pain
Primary: Change From Baseline in Brief Pain Inventory (BPI) Questionnaire Item 6 "Pain Right Now" Score at Week 24 (Per Protocol [PP] Population) — -2.8; -3.2 Units on a scale…
Phase 4 N=120 Methadone and Hydromorphone For Spinal Surgery
Hydromorphone Use · Acute Postoperative Pain · Patient Satisfaction
Primary: Hydromorphone Use at 24 Hours — 4.56; 9.9 milligrams
Phase 4 N=350 Comparing Intravenous Hydromorphone to Usual Care
Pain
Primary: Number of Participants Who Declined Additional Medication at 30 Minutes — 127; 106 Participants
N/A N=134 Spinal Morphine vs. Hydromorphone for Pain Control After Cesarean Delivery
Analgesia, Obstetrical · Obstetric Surgical Procedures
Primary: NRS Score for Pain (0-10) With Movement 24 Hours After Spinal Administration — 4; 3 score on a scale — p=0.132
Phase 2 N=20 Hydromorphone and C-section
Postoperative Pain
Primary: Pain Scores, Visual Analogue Pain Scale — 2.75 units on a scale
Phase 4 N=116 An Open-label Study of Hydromorphone Oral Solution in Subjects Aged 28 Days to 16 Years for Postoperative Pain
Postoperative Pain
Primary: Population Pharmacokinetic/Pharmacodynamic (PK/PD) Model for Hydromorphone: Clearance (Cl) — 114 L/hour
Phase 2 N=35 Intranasal Hydromorphone for the Treatment of Acute Pain in Children: A Pilot Study.
Pain
Primary: Score on Faces Pain Scale - Revised — 4.7 units on a scale
Phase 3 N=194 Trial Comparing Morphine to Hydromorphone in Elderly Patients With Severe Pain
Acute Pain
Primary: Change in Pain Intensity — 3.3; 3.8 units on a scale
N/A N=50 The Effects of Hydromorphone on Responses to Verbal Tasks
Healthy
Primary: Subjective Effects as Assessed by Score on "Feel Drug", "Feel High", "Like Drug", and "Want More" Subscales of the Drug Effects Questionnaire — 7.41; 14.75; 28; 5.76…
Phase 2 N=298 Safety of Hydromorphone in Adult Patients Presenting to the Emergency Department With Acute Severe Pain
Acute Pain
Primary: Number of Participants Requiring Naloxone — 0 Participants
Phase 3 N=153 Safety and Efficacy Study of Hydromorphone Hydrochloride by Intrathecal Administration
Management of Chronic Pain
Primary: Proportion of Subjects Who Are Treatment Failures During the Double-blind Randomized Withdrawal Period — 18; 24 Participants — p=0.147
Phase 2 N=22 Intrathecal Hydromorphone for Labor Analgesia
Labor Pain
Primary: Pain Score, Visual Analogue Pain Scores — 1.9 units on a scale
N/A N=402 Satisfactory Analgesia Minimal Emesis in Day Surgeries
Pain · Post Operative Nausea and Vomiting
Primary: Our Combined Primary Outcome Will be Number of Patients With Same Analgesia Minimal Emesis, as Compared Between the 2 Groups. — 172; 175 Participants — p=0.997
Phase 3 N=260 An Efficacy and Safety Study of Oral Osmotic Therapeutic System (OROS) Hydromorphone Hydrochloride (HCl) in Participants With Cancer Related Pain
Pain
Primary: Change From Baseline in Worst Pain in the Past 24 Hours Assessed by Brief Pain Inventory (BPI) Short Form Questionnaire Score at Day 29 — 6.7; 6.9; -1.8; -1.8 Units on a…
Phase 4 N=127 Hydromorphone Versus Prochlorperazine + Diphenhydramine for Acute Migraine
Migraine
Primary: Number of Participants With Sustained Headache Relief Assessed by Self-evaluation — 20; 37 Participants
Phase 3 N=364 Single-arm Study to Assess the Safety of Hydromorphone Hydrochloride by Intrathecal Administration
Chronic Pain
Primary: Granulomas — 12; 352; 0; 0 Participants
Phase 4 N=230 Safety Study of Intravenous Hydromorphone Using Incremental 1mg Doses up to 2mg for Adult ED Patients
Pain
Primary: Number of Patients Who Had Adequate Analgesia — 51; 172; 9; 35 Participants
Phase 4 N=54 Ketamine vs Hydromorphone
Laparoscopic Gastric Bypass · Obesity · Pain, Postoperative
Primary: Pain Measured Based on Pain Medication Used on a Scale of 0-10 — 1.3; 0.7 units on a scale
Phase 4 N=84 Intrathecal Opioids for Pain Control After Cesarean Delivery: Determining the Optimal Dose
Analgesia, Obstetrical · Cesarean Section
Primary: Dose of IT Morphine and IT Hydromorphone for Adequate Analgesia (Pain Score Less Than or Equal to 3) in 90% of Patients — 75; 150 micrograms
Phase 2 N=162 Acetaminophen Versus IV Hydromorphone for Pain in the Elderly in the ED
Acute Pain
Primary: Clinical Improvement in NRS Pain Score — 62; 63 Participants
Phase 3 N=350 Clinical Trial Comparing Two Protocols Using Intravenous (IV) Hydromorphone
Acute Pain
Primary: Number of Patients With Satisfactory Pain Management at 60 Minutes — 112; 113 Participants
Phase 3 N=350 Protocolized vs Discretionary Use of Opioids in Acute Pain
Pain
Primary: Percentage of Patients With Successful Treatment — 86.8; 76.6 Percentage of Participants
Phase 3 N=162 IV Acetaminophen as Adjuvant Analgesic to Hydromorphone - Emergency Department Patients
Acute Pain
Primary: Change in Numerical Rating Scale of Pain (NRS) Before Treatment to 60 Minutes After Treatment — 6.2; 5.4 units on a scale — p=0.08
Early Phase 1 N=188 Hydromorphone vs Fentanyl in Children Undergoing Tonsillectomy Surgery
Obstructive Sleep Apnea · Tonsillitis
Primary: Number of Patients Requiring Rescue Intravenous Opioid — 48; 66 Participants
Phase 4 N=141 An Efficacy and Safety Study of Hydromorphone Hydrochloride (HCl) Oral Osmotic System (OROS) in the Reduction of Breakthrough Pain Medication Frequency in Participants With Cancer
Cancer · Pain
Primary: Percentage of Participants With Dosing Frequency of Analgesics for Treating Breakthrough Pain — 50.9 Percentage of Participants
Phase 3 N=459 Study to Test the Effectiveness of Controlled-Release OROS® Hydromorphone HCl Compared to Placebo in Patients With Chronic Low Back Pain
Chronic Low Back Pain
Primary: Change From Baseline to Week 12 in Mean Pain Intensity — 0.6; 1.7 score on a scale